Why Correcting Trial Imaging Errors at Central Review Is Too Late—and Too Expensive
The patient drove two hours each way for the trial, which her oncologist and she believed was her best...
Clinuvel’s Novel Formulations Advance in Preclinical Program
CLINUVEL has advanced a portfolio of sustained‑release liquid depot formulations for peptides into preclinical testing, targeting predictable release kinetics...
Northwell Christina Brennan on Future of Site-Sponsor Partnerships
At the Veeva R&D and Quality Summit in Boston, we interviewed Dr. Christina Brennan, Senior Vice President of Clinical...
Breakthrough: NIH Funds Alzheimer’s Drug AD04 with $2.5M
ADvantage Therapeutics secured a $2.5 million Phase II SBIR grant from the National Institute on Aging to advance AD04,...
Immuneering to Discuss Pancreatic Cancer Survival Data
Updated overall survival and safety data from a 34‑patient, first‑line pancreatic cancer cohort treated with atebimetinib plus modified gemcitabine/nab‑paclitaxel...
Groundbreaking Data: Revita Maintains Weight Loss Post-GLP-1
In a randomized, double-blind, sham-controlled midpoint cohort of REMAIN-1 (N=45), Revita produced an additional 2.5% total body weight loss...
Organogenesis Gives Update on Second Phase 3 Renu® Study
ReNu’s second Phase 3 randomized trial in symptomatic knee osteoarthritis missed its primary endpoint, showing a 0.5-point advantage over...
Cidara Doses Patients in Phase 3 Flu Prevention Trial
Cidara has begun dosing in ANCHOR, a global Phase 3 trial of CD388, a single 450 mg subcutaneous dose...
AbbVie’s Rinvoq: A Surging New Option for GCA Treatment
Forty percent of rheumatologists report initiating Rinvoq (upadacitinib) for giant cell arteritis (GCA) within weeks of approval, with nearly...
First Fully Robotic GI Procedure by a Gastroenterologist
In the PARADIGM pivotal IDE trial, a gastroenterologist completed the first fully robotic endoscopic submucosal dissection using EndoQuest’s Endoluminal...